MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To guage a number of intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Major trial objectives ended up To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, when one of https://davidx110jvf3.madmouseblog.com/profile